Clinical Trials Logo

Clinical Trial Summary

A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary disease (COPD). ⚠️study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).


Clinical Trial Description

In the first study period (Period 1), patients with moderate to severe persistent asthma according to GINA criteria, with or without COPD, will be randomized at a 1: 1 ratio to receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12 weeks Participants who maintain asthma control at the end of this treatment period (no more than one exacerbation during this period) will be included in Period 2, in which the dose of each investigational product will be reduced (step-down), and the patients will receive formoterol 6mcg / budesonide 200mcg Eurofarma or Alenia® 6mcg / 200mcg, respectively, for an additional 12 weeks. The primary non-inferiority assessment will be performed at the end of 24 weeks of treatment, with intermediate assessment at the end of week 12. The study will be conducted in an open label since the devices for inhalation of products have different aspects, making it impossible to blind the treatments of the study. The primary efficacy variable (forced expiratory volume in one second [FEV1]) minimizes the potential bias arising from the open label of the study. ⚠️study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04233190
Study type Interventional
Source Eurofarma Laboratorios S.A.
Contact Gleyce Lima
Phone 55 11 5090 8411
Email gleyce.lima@eurofarma.com
Status Recruiting
Phase Phase 3
Start date April 19, 2023
Completion date November 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06099145 - Clinical and Medico-economic Validation of the HEPHAI Solution. N/A
Completed NCT06417931 - Medication Adherence and Use of Inhaler Devices in Patients With Asthma or COPD N/A
Completed NCT05764343 - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases N/A
Recruiting NCT06039943 - Relationship Between Acoustic Breath Sounds and Spirometry N/A
Active, not recruiting NCT05006521 - Single and Multiple Ascending Dose Study of KN-002 Phase 1
Recruiting NCT05299385 - The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) Phase 3
Active, not recruiting NCT04341701 - Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases N/A